Tumor P-glycoprotein correlates with efficacy of PF-3758309 in in vitro and in vivo models of colorectal cancer

Erica Lynn Bradshaw-Pierce, Todd M. Pitts, Aik Choon Tan, Kelly McPhillips, Mark West, Daniel L. Gustafson, Charles Halsey, Leslie Nguyen, Nathan V. Lee, Julie L.C. Kan, Brion William Murray, S. Gail Eckhardt

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

P-glycoprotein (P-gp), a member of the ATP-binding cassette transporter family, is overexpressed in a number of different cancers and some studies show that P-gp overexpression can be correlated to poor prognosis or therapeutic resistance. Here we sought to elucidate if PF-3758309 (PF-309), a novel p-21 activated kinase inhibitor, efficacy was influenced by tumor P-gp. Based on in vitro proliferation data, a panel of colorectal cancer cell lines were ranked as sensitive or resistant and ABCB1 (P-gp) expression was evaluated by microarray for these cell lines. P-gp expression was determined by western blot and activity determined by rhodamine efflux assay. Knock down of P-gp and pharmacologic inhibition of P-gp to restore PF-309 activity was performed in vitro. PF-309 activity was evaluated in vivo in cell line xenograft models and in primary patient derived tumor xenografts (PDTX). Mice were treated with 25 mg/kg PF-309 orally, twice daily. On the last day of treatment, tumor and plasma were collected for PF-309 analysis. Here we show that ABCB1 gene expression correlates with resistance to PF-309 treatment in vitro and the expression and activity of P-gp was verified in a panel of resistant cells. Furthermore, inhibition of P-gp increased the sensitivity of resistant cells, resulting in a 4-100-fold decrease in the IC50s. Eleven cell line xenografts and 12 PDTX models were treated with PF-309. From the cell line xenografts, we found a significant correlation between ABCB1 gene expression profiles and tumor response. We evaluated tumor and plasma concentrations for eight tumor models (three cell line xenografts and five PDTX models) and a significant correlation was found between tumor concentration and response. Additionally, we show that tumor concentration is approximately fourfold lower in tumors that express P-gp, verified by western blot. Our in vitro and in vivo data strongly suggests that PF-309 efficacy is influenced by the expression of tumor P-gp.

Original languageEnglish
Article numberArticle 22
JournalFrontiers in Pharmacology
Volume4 MAR
DOIs
Publication statusPublished - 2013

Keywords

  • Colorectal cancer
  • Intrinsic resistance
  • Mouse xenografts
  • P-glycoprotein
  • Pf-3758309

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Tumor P-glycoprotein correlates with efficacy of PF-3758309 in in vitro and in vivo models of colorectal cancer'. Together they form a unique fingerprint.

  • Cite this

    Bradshaw-Pierce, E. L., Pitts, T. M., Tan, A. C., McPhillips, K., West, M., Gustafson, D. L., Halsey, C., Nguyen, L., Lee, N. V., Kan, J. L. C., Murray, B. W., & Eckhardt, S. G. (2013). Tumor P-glycoprotein correlates with efficacy of PF-3758309 in in vitro and in vivo models of colorectal cancer. Frontiers in Pharmacology, 4 MAR, [Article 22]. https://doi.org/10.3389/fphar.2013.00022